Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;39(2):212-217.
doi: 10.1017/S1049023X24000128. Epub 2024 Mar 7.

Adverse Effects After Prehospital Administration of Naloxone by Bystanders: A Preliminary Study

Daniel Du Pont  1 , Rebecca Fenderson  2 , Krystal Hunter  3 , Alexander Kuc  4 , Gerard Carroll  4
Affiliations

Adverse Effects After Prehospital Administration of Naloxone by Bystanders: A Preliminary Study

Daniel Du Pont et al. Prehosp Disaster Med. 2024 Apr.

Abstract

Objective: Opioid use disorder is a cause of significant morbidity and mortality. In order to reverse opioid overdose as quickly as possible, many institutions and municipalities have encouraged people with no professional medical training to carry and administer naloxone. This study sought to provide preliminary data for research into the rates of adverse effects of naloxone when administered by bystanders compared to Emergency Medical Services (EMS) personnel, since this question has not been studied previously.

Methods: This was a retrospective cohort study performed at an urban, tertiary, academic medical center that operates its own EMS service. A consecutive sample of patients presenting to EMS with opioid overdose requiring naloxone was separated into two groups based on whether naloxone was administered by bystanders or by EMS personnel. Each group was analyzed to determine the incidence of four pre-specified adverse events.

Results: There was no significant difference in the rate of adverse events between the bystander (19%) and EMS (16%) groups (OR = 1.23; 95% CI, 0.63 - 2.32; P = .499) in this small sample. Based on these initial results, a study would need a sample size of 6,188 in order to reach this conclusion with 80% power. Similarly, there were no significant differences in the rates of any of the individual adverse events. Secondary analysis of patients' demographics showed differences between the two groups which generate hypotheses for further investigation of disparities in naloxone administration.

Conclusions: This preliminary study provides foundational data for further investigation of naloxone administration by bystanders. Adverse events after the prehospital administration of naloxone are rare, and future studies will require large sample sizes. These preliminary data did not demonstrate a statistically significant difference in adverse event rates when comparing naloxone administration by bystanders and EMS clinicians. This study provides data that will be useful for conducting further research on multiple facets of this topic.

Keywords: bystander; naloxone; opiate; opioid; overdose.

PubMed Disclaimer

Conflict of interest statement

The authors declare none.

Figures

Figure 1.
Figure 1.
Patient Selection. Abbreviations: ALS, Advanced Life Support; BLS, Basic Life Support; EMS, Emergency Medical Services.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Centers for Disease Control and Prevention. Web-based Injury Statistics Query and Reporting System (WISQARS): CDC’s National Center for Injury Prevention and Control. www.cdc.gov/injury/wisqars. Accessed June 15, 2023.
    1. Ahmad FB, Cisewski JA, Rossen LM, et al. Provisional drug overdose death counts. National Center for Health Statistics. 2023. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed June 15, 2023.
    1. Ashburn NP, Ryder CW, Angi RM, et al. One-year mortality and associated factors in patients receiving out-of-hospital naloxone for presumed opioid overdose. Ann Emerg Med. 2020;75(5):559–567. - PubMed
    1. FDA Approves First Over-the-Counter Naloxone Nasal Spray. FDA.gov. Published online March 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-o.... Accessed June 15, 2023.
    1. Briefing Document, Joint Meeting of the Nonprescription Drug and the Anesthetic and Analgesic Drug Products Advisory Committees. Topic: Rx-to-OTC switch for NARCAN (naloxone HCl) Nasal Spray 4 mg, NDA 208411, Meeting Date: February 15, 2023. https://www.fda.gov/media/165339/download. Accessed June 15, 2023.